论文部分内容阅读
目的改进子宫内膜异位临床药物治疗方式,增强治疗的有效性,为女性的身体健康提供保障。方法将研究对象随机划分为观察组与对照组,两组人数分别33例,确保两组在各项临床数据上的可比性。分别对观察组与对照组患者采用不同的药物治疗方式,并对治疗结果进行数据分析。结果通过12个月的回访调查发现,观察组中的33例患者在经治疗后,获得显效治疗的患者有22例,获得有效治疗的患者有8例,治疗无效的患者有3例,总有效率为90.9%,复发的患者有4例,复发率为12.12%;对照组中的33例患者在经治疗后,获得显效治疗的患者有12例,获得有效治疗的患者有5例,治疗无效的患者有16例,总有效率为51.51%,复发的患者有14例,复发率为42.42%。两组疗效对比差异有统计学意义。结论口服米非司酮配合丹莪妇康颗粒比口服避孕药或应用促性腺激素等传统用药治疗方式,能够取得更好的子宫内膜异位治疗效果,值得临床推广。
Objective To improve the treatment of endometriosis clinical drugs and enhance the effectiveness of treatment to provide protection for the health of women. Methods Subjects were randomly divided into observation group and control group. There were 33 cases in both groups, which ensured the comparability of clinical data between the two groups. The patients in the observation group and the control group were treated with different drugs, and the data of the treatment were analyzed. Results A 12-month follow-up survey found that 33 of the 33 patients in the observation group achieved marked response after treatment, 22 were effective, 8 were ineffective, and 3 were ineffective The efficiency was 90.9%, 4 patients relapsed, the recurrence rate was 12.12%; 33 patients in the control group after treatment, effective treatment of patients in 12 cases, effective treatment of patients in 5 cases, the treatment is invalid Of patients were 16 cases, the total effective rate was 51.51%, 14 patients relapsed, the recurrence rate was 42.42%. The difference between the two groups was statistically significant. Conclusion Oral mifepristone combined with Dan Curcuma particles than oral contraceptives or the application of gonadotropin and other traditional drug treatment, can achieve better endometriosis effect, worthy of clinical promotion.